Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation

The genetic landscape and molecular features of collecting duct carcinoma (CDC) of the kidney remain largely unknown. Herein, we performed whole exome sequencing (WES) and transcriptome sequencing (RNASeq) on 7 CDC samples (CDC1 −7). Among the 7 samples, 4 samples with matched non-tumor tissue were used for copy number analysis by SNP array data. No recurrent somatic SNVs were observed except for MLL, which was found to be mutated (p.V297I and p.F407C) in 2 samples. We identified somatic SNVs in 14 other cancer census genes including: ATM, CREBBP, PRDM1, CBFB, FBXW7, IKZF1, KDR, KRAS, NACA, NF2, NUP98, SS18, TP53, and ZNF521. SNP array data identified a CDKN2A homozygous deletion in 3 samples and SNV analysis showed a non-sense mutation of the CDKN2A gene with unknown somatic status. To estimate the recurrent rate of CDKN2A abnormalities, we performed FISH screening of additional samples and confirmed the frequent loss (62.5%) of CDKN2A expression. Since cisplatin based therapy is the common treatment option for CDC, we investigated the expression of solute carrier (SLC) family transporters and found 45% alteration. In addition, SLC7A11 (cystine transporter, xCT), a cisplatin resistance associated gene, was found to be overexpressed in 4 out of 5 (80%) cases of CDC tumors tested, as compared to matched non-tumor tissue. In summary, our study provides a comprehensive genomic analysis of CDC and identifies potential pathways suitable for targeted therapies.

[1]  P. Stephens,et al.  Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. , 2016, European urology.

[2]  Jie Fan,et al.  Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer , 2016, Cancer biology & therapy.

[3]  Reuven Agami,et al.  Tumour-specific proline vulnerability uncovered by differential ribosome codon reading , 2016, Nature.

[4]  Jianmin Zhang,et al.  YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage , 2015, Oncogene.

[5]  Peng Huang,et al.  Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. , 2015, Cancer letters.

[6]  Beata Smolska-Ciszewska,et al.  Collecting (Bellini) duct carcinoma: A clinical study of a rare tumour and review of the literature. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[7]  G. Semenza,et al.  Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype , 2015, Proceedings of the National Academy of Sciences.

[8]  K. Giacomini,et al.  SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.

[9]  A. Fusco,et al.  Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas , 2015, Front. Med..

[10]  J. Stenvang,et al.  The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells , 2015, BMC Cancer.

[11]  Z. Qin,et al.  xCT, not just an amino-acid transporter: a multi-functional regulator of microbial infection and associated diseases , 2015, Front. Microbiol..

[12]  Gurmit Singh,et al.  Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain , 2015, Scientific Reports.

[13]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[14]  Terrence S. Furey,et al.  GSAASeqSP: A Toolset for Gene Set Association Analysis of RNA-Seq Data , 2014, Scientific Reports.

[15]  Lian-tang Wang,et al.  Overexpression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer , 2014, Oncotarget.

[16]  Yangchao Chen,et al.  Novel therapeutic targets for pancreatic cancer. , 2014, World journal of gastroenterology.

[17]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[18]  K. Itoh,et al.  Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition , 2014, Molecular and Cellular Biology.

[19]  Ryoichi Fujiwara,et al.  Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders , 2014, Scientific Reports.

[20]  Hyo Song Kim,et al.  Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[21]  M. Sayé,et al.  Proline Modulates the Trypanosoma cruzi Resistance to Reactive Oxygen Species and Drugs through a Novel D, L-Proline Transporter , 2014, PloS one.

[22]  A. Hartmann,et al.  Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11 , 2014, Clinical Cancer Research.

[23]  M. Colecchia,et al.  Treatment of collecting duct carcinoma: current status and future perspectives. , 2014, Anticancer research.

[24]  Y. Allory,et al.  Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Grobholz,et al.  Collecting Duct Carcinomas Represent a Unique Tumor Entity Based on Genetic Alterations , 2013, PloS one.

[26]  J. Gray,et al.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.

[27]  C. Stief,et al.  Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. , 2013, The Journal of urology.

[28]  A. Kapoor,et al.  Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. , 2013, Current oncology.

[29]  N. Grishin,et al.  A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma , 2013, Molecular Cancer Research.

[30]  Jingjing Wu,et al.  HMGA2 and high-grade serous ovarian carcinoma , 2013, Journal of Molecular Medicine.

[31]  Liangren Liu,et al.  Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature , 2013, International Urology and Nephrology.

[32]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[33]  J. Stenvang,et al.  Colorectal cancer cell lines made resistant to SN38‐and Oxaliplatin: Roles of altered ion transporter function in resistance? , 2013 .

[34]  P. Zawierucha,et al.  Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[35]  M. Leuenberger,et al.  The SLC1 high-affinity glutamate and neutral amino acid transporter family. , 2013, Molecular aspects of medicine.

[36]  K. Tsuchihashi,et al.  xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. , 2013, Cancer research.

[37]  S. S. Koh,et al.  Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. , 2013, Carcinogenesis.

[38]  P. Kalivas,et al.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. , 2013, Antioxidants & redox signaling.

[39]  Y. Siregar.  Oncogene and Cancer - From Bench to Clinic , 2013 .

[40]  Wei Liu,et al.  MiRNA and Proline Metabolism in Cancer , 2013 .

[41]  Lisa L. Smith,et al.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.

[42]  M. Bronchud,et al.  HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report , 2012, Oncology Research and Treatment.

[43]  R. Shah,et al.  Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma: Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma With a Focus on Their Interrelationship , 2012, The American journal of surgical pathology.

[44]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[45]  J. Catto,et al.  Molecular mechanisms of cisplatin resistance in bladder cancer , 2012, Expert review of anticancer therapy.

[46]  A. Horchani,et al.  [Bellini renal cell carcinoma : diagnosis and treatment. A report of 7 cases]. , 2011, La Tunisie medicale.

[47]  H. M’rabti,et al.  WORLD JOURNAL OF SURGICAL ONCOLOGY , 2022 .

[48]  Kenneth H. Buetow,et al.  Bioinformatics Applications Note Sequence Analysis Bambino: a Variant Detector and Alignment Viewer for Next-generation Sequencing Data in the Sam/bam Format , 2022 .

[49]  S. Dangi‐Garimella,et al.  Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. , 2011, Cancer research.

[50]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[51]  Oliver Sieber,et al.  A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data , 2010, Genome Biology.

[52]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[53]  M. Yin,et al.  Downregulation of Cystine Transporter xc– by Irinotecan in Human Head and Neck Cancer FaDu Xenografts , 2010, Chemotherapy.

[54]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[55]  J. Wright,et al.  Effect of collecting duct histology on renal cell cancer outcome. , 2009, The Journal of urology.

[56]  Ju-Han Lee,et al.  Genetic alterations and chemosensitivity profile in newly established human renal collecting duct carcinoma cell lines , 2009, BJU international.

[57]  B. Delahunt,et al.  Uncommon and recently described renal carcinomas , 2009, Modern Pathology.

[58]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[59]  S. Lam,et al.  The xc− cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine , 2009, Cancer Chemotherapy and Pharmacology.

[60]  S. Naito,et al.  Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.

[61]  M. Martinka,et al.  Aberrant Expression of Collagen Triple Helix Repeat Containing 1 in Human Solid Cancers , 2006, Clinical Cancer Research.

[62]  Y. Sadzuka,et al.  Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. , 2003, Biochimica et biophysica acta.

[63]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[64]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[65]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.